177 related articles for article (PubMed ID: 38272991)
21. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.
Dillon LW; Higgins J; Nasif H; Othus M; Beppu L; Smith TH; Schmidt E; Valentine Iii CC; Salk JJ; Wood BL; Erba HP; Radich JP; Hourigan CS
Haematologica; 2024 Feb; 109(2):401-410. PubMed ID: 37534515
[TBL] [Abstract][Full Text] [Related]
22. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
23. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia.
Ding Y; Liu Z; Wang H; Xiong S; Zhai Z
Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341
[TBL] [Abstract][Full Text] [Related]
25. Normal or reactive minor cell populations in bone marrow and peripheral blood mimic minimal residual leukemia by flow cytometry.
Li W; Morgan R; Nieder R; Truong S; Habeebu SSM; Ahmed AA
Cytometry B Clin Cytom; 2021 Sep; 100(5):590-601. PubMed ID: 33197125
[TBL] [Abstract][Full Text] [Related]
26. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
27. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
28. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia.
Terwijn M; Kelder A; Snel AN; Rutten AP; Scholten WJ; Oussoren YJ; Van De Loosdrecht AA; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
Int J Lab Hematol; 2012 Aug; 34(4):432-41. PubMed ID: 22471741
[TBL] [Abstract][Full Text] [Related]
30. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
Setiadi A; Owen D; Tsang A; Milner R; Vercauteren S
Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
[TBL] [Abstract][Full Text] [Related]
31. The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease.
Hsu FC; Hudson C; Wilson ER; Pardo LM; Singleton TP; Xu D; Zehentner BK; Hitzler J; Berman J; Wells DA; Loken MR; Brodersen LE
Cytometry B Clin Cytom; 2023 Jul; 104(4):311-318. PubMed ID: 37015883
[TBL] [Abstract][Full Text] [Related]
32. [Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Multi-color Flow Cytometry].
He C; Zhang QT; Tang P; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):341-345. PubMed ID: 35395960
[TBL] [Abstract][Full Text] [Related]
33. Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them.
Li SQ; Chen M; Huang XY; Wang H; Chang YJ
Expert Rev Hematol; 2023; 16(12):981-990. PubMed ID: 37978882
[TBL] [Abstract][Full Text] [Related]
34. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic significance of minimal residual disease detected by multiparameter flow cytometry in acute myeloid leukemia].
Wang YZ; Liu YR; Zhu HH; Wu HH; Cao H; Chan Y; Hao L; Jiang B; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):551-6. PubMed ID: 19549362
[TBL] [Abstract][Full Text] [Related]
36. Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia.
Maurer-Granofszky M; Kohrer S; Fischer S; Schumich A; Nebral K; Larghero P; Meyer C; Mecklenbrauker A; Muhlegger N; Marschalek R; Haas OA; Panzer-Grumayer R; Dworzak MN
Haematologica; 2024 Mar; 109(3):740-750. PubMed ID: 37345487
[TBL] [Abstract][Full Text] [Related]
37. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
38. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
[TBL] [Abstract][Full Text] [Related]
39. Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.
Orvain C; Wilson JA; Fang M; Sandmaier BM; Rodríguez-Arbolí E; Wood BL; Othus M; Appelbaum FR; Walter RB
Haematologica; 2023 Feb; 108(2):420-432. PubMed ID: 35924583
[TBL] [Abstract][Full Text] [Related]
40. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM
J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]